Endo Files Response With FDA on Nebido Safety Questions

Endo Pharmaceuticals said that the Food and Drug Administration has accepted for review its subsidiary’s complete response to safety questions the agency has raised about a new drug application for Nebido.
Philadelphia Business Journal